Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
3TC (Lamivudine; GR109714X) Open-Label Program Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on 3TC (Lamivudine; GR109714X) Open-Label Program conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. 3TC (Lamivudine; GR109714X) Open-Label Program Clinical research trials and 3TC (Lamivudine; GR109714X) Open-Label Program medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like 3TC (Lamivudine; GR109714X) Open-Label Program. 3TC (Lamivudine; GR109714X) Open-Label Program Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a 3TC (Lamivudine; GR109714X) Open-Label Program clinical trial. Subjects typically recieve the finest healthcare available for their 3TC (Lamivudine; GR109714X) Open-Label Program condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.

Home > "3" Clinical Trials Conditions > 3TC (Lamivudine; GR109714X) Open-Label Program

3TC (Lamivudine; GR109714X) Open-Label Program



3TC (Lamivudine; GR109714X) Open-Label Program

For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies. To collect data pertaining to the safety of 3TC at two dose levels. To evaluate the effect of 3TC on markers of hepatitis B in co-infected patients at five to ten selected sites.
Details: Patients 12 years and older are randomized to receive one of two doses of 3TC for a duration determined by the patient's physician or until termination of the program. Patients < 12 years receive a lower dose of 3TC. Patients are followed monthly. For selected sites only, serum samples are collected every 3 months from patients identified as HBsAg positive. PER 02/28/95 AMENDMENT: Patients enrolled prior to 3/1/95 may remain on their assigned monotherapy dose or change to combination therapy with 3TC and zidovudine.
Eligibility:
Study Type:  Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 3 Years/
Genders: Both
Protocol Entry Criteria: Patients must: - Have progressive, symptomatic HIV disease. - Have a mean CD4 count <= 99 cells/mm3 for adults and <= 300 cells/mm3 for children (original design was CD4 count <= 300 cells/mm3 for both adults and children). - Be unable to participate in a controlled trial. - Be refractory to or unable to tolerate other therapies. - Be able to attend clinic on a monthly schedule. - Have consent of parent or guardian if under the age of consent. NOTE: - If a pregnant or breast-feeding woman requests enrollment, her physician should contact Glaxo staff directly to discuss the case. Practice of unsafe sex.
Total Enrollment: 

Location and Contact Information:

Kern - McNeill International
Morristown,  New Jersey,  07960
United States
 


Additional Information:
Study ID Numbers:  129D;  NUCA 3004
Study Start Date: 
Record last reviewed: November 1995
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002108

Other Hiv Infections Studies:
1. The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

2. T-20 in HIV Patients with Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs

3. Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children

4. The Effects of Illnesses on HIV Levels in the Body

5. Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents

Related Studies:

Other HIV Infections Clinical Trials
Other New Jersey Clinical Trials
Other Morristown Clinical Trials

3TC (Lamivudine; GR109714X) Open-Label Program
Modify your Search

  Other HIV Infections Clinical Trials
  Other New Jersey Clinical Trials
  Other Morristown Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103